Core Viewpoint - The company, Shanxi Panlong Pharmaceutical Group Co., Ltd., is revising its Articles of Association and related corporate governance systems to enhance governance efficiency and streamline management processes, including the abolition of the supervisory board and the transfer of its responsibilities to the audit committee of the board of directors [1][2][3]. Summary by Sections Revision of Articles of Association - The company plans to amend its Articles of Association to comply with the latest regulatory framework and improve governance effectiveness [1][2]. - The supervisory board will be dissolved, and its functions will be transferred to the audit committee, pending approval from the shareholders' meeting [1][2]. Specific Amendments - The amendments will include changes to the roles and responsibilities of the board of directors and the legal representative of the company [4][5]. - The new provisions will clarify that the legal representative's civil activities will be the company's responsibility, and the company can seek compensation from the legal representative if damages occur due to their duties [4][5]. Governance Structure Changes - The supervisory board's responsibilities will cease upon the approval of the revised Articles of Association, and the rules governing the supervisory board will be abolished [2][3]. - The company will ensure that the audit committee will diligently perform its supervisory functions until the shareholders' meeting approves the changes [2][3]. Legal Compliance - The revisions are in accordance with the Company Law, Securities Law, and relevant regulations from the Shenzhen Stock Exchange [3][4]. - The company emphasizes that the amendments aim to protect the rights and interests of shareholders, employees, and creditors while ensuring compliance with legal requirements [1][2].

Core Viewpoint - The independent director candidate, Niu Xiaofeng, has been nominated for the fifth board of directors of Shaanxi Panlong Pharmaceutical Group Co., Ltd. by the controlling shareholder, Xie Xiaolin, who has made a public declaration regarding the nomination [1]. Group 1: Nomination Process - The nomination was made after a thorough understanding of the candidate's professional background, education, qualifications, work experience, and any significant dishonesty records [1]. - The candidate has agreed in writing to serve as an independent director [1]. Group 2: Compliance with Regulations - The candidate has passed the qualification review by the company's fourth board of directors' nomination committee [2]. - The candidate does not have any disqualifying conditions as per the Company Law of the People's Republic of China [2]. - The candidate meets the qualifications and conditions for independent directors as stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange [2][3]. Group 3: Independence and Experience - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2]. - The candidate possesses basic knowledge related to the operation of listed companies and has over five years of relevant work experience in law, economics, management, accounting, or finance [5][10]. - The candidate is not currently serving in any position within the company or its subsidiaries [5]. Group 4: Commitment and Accountability - The nominator guarantees that the declaration is true, accurate, and complete, and is willing to bear legal responsibility for any false statements [10]. - The nominator has authorized the company secretary to submit the declaration to the Shenzhen Stock Exchange and make it public [10]. - If the candidate's independence is compromised during their tenure, the nominator will report this to the board and urge the candidate to resign [10].

Group 1 - The candidate Wang Mancang has been nominated as an independent director for the fifth board of Shaanxi Panlong Pharmaceutical Group Co., Ltd. by the controlling shareholder Xie Xiaolin [1] - The candidate confirms that there are no relationships that could affect his independence and meets the qualifications required by relevant laws and regulations [1][2] - The candidate has undergone qualification review by the nomination committee of the fourth board and has no conflicting interests with the nominator [1][2] Group 2 - The candidate affirms compliance with the requirements set forth by the China Securities Regulatory Commission and the Shenzhen Stock Exchange for independent directors [2][4] - The candidate has completed training and obtained relevant certification recognized by the stock exchange [2][5] - The candidate declares that he does not hold any position in the company or its subsidiaries, nor does he or his immediate family hold more than 1% of the company's shares [5][6][7] Group 3 - The candidate has no significant business dealings with the company or its controlling shareholders [7][8] - The candidate has not been subject to any criminal penalties or administrative sanctions related to securities in the past 36 months [7][8] - The candidate commits to fulfilling the responsibilities of an independent director diligently and independently, without influence from major shareholders or related parties [9]

陕西盘龙药业集团股份有限公司 独立董事提名人声明与承诺 提名人控股股东谢晓林现就提名王满仓为陕西盘龙药业集团股 份有限公司第五届董事会独立董事候选人发表公开声明。被提名人已 书面同意作为陕西盘龙药业集团股份有限公司第五届董事会独立董 事候选人(参见该独立董事候选人声明)。本次提名是在充分了解被提 名人职业、学历、职称、详细的工作经历、全部兼职、有无重大失信 等不良记录等情况后作出的，本提名人认为被提名人符合相关法律、 行政法规、部门规章、规范性文件和深圳证券交易所业务规则对独立 董事候选人任职资格及独立性的要求，具体声明并承诺如下事项: 一、被提名人已经通过陕西盘龙药业集团股份有限公司第四届董 事会提名委员会或者独立董事专门会议资格审查，提名人与被提名人 不存在利害关系或者其他可能影响独立履职情形的密切关系。 是□ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条 等规定不得担任公司董事的情形。 是□ 否 如否，请详细说明：______________________________ 三、被提名人符合中国证监会《上市公 ...

Core Viewpoint - The independent director candidate, Niu Xiaofeng, has declared his commitment to the position and confirmed his independence from any relationships that could affect his role [1][9]. Group 1: Candidate Qualifications - The candidate has undergone qualification review by the company's nomination committee and has no conflicting interests with the nominator [1]. - The candidate meets the requirements set forth by the Company Law of the People's Republic of China regarding disqualifications for serving as a director [2]. - The candidate complies with the independent director qualifications as per the China Securities Regulatory Commission and Shenzhen Stock Exchange regulations [2][4]. Group 2: Compliance and Training - The candidate has participated in training and possesses the necessary certification recognized by the stock exchange [2]. - The candidate's role as an independent director will not violate any relevant laws or regulations, including those from the Central Commission for Discipline Inspection [2][3]. Group 3: Independence Assurance - The candidate confirms that neither he nor his immediate family members hold any shares exceeding 1% in the company or are among the top ten shareholders [5][6]. - The candidate has no significant business dealings with the company or its major shareholders [7]. - The candidate has not been subject to any criminal penalties or administrative sanctions related to securities in the past 36 months [7][8]. Group 4: Responsibilities and Reporting - The candidate acknowledges the responsibilities of an independent director and commits to fulfilling these duties diligently [9]. - The candidate will report any changes in his qualification status to the board and resign if he no longer meets the criteria [9].

证券代码：002864 证券简称：盘龙药业 公告编号：2025-033 陕西盘龙药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据中国证券监督管理委员会发布的《上市公司募集资金监管规则》、《深圳证券交 易所上市公司自律监管指引第 1 号——主板上市公司规范运作》以及《深圳证券交易所上 市公司自律监管指南第 2 号——公告格式（2025 年修订）》等有关规定，陕西盘龙药业 集团股份有限公司（以下简称"公司"）公司编制了截至 2025 年 6 月 30 日的《2025 年 半年度募集资金存放与使用情况的专项报告》。现将相关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会许可【2021】3323 号核准，公司于 2022 年 3 月 3 日发行 可转换公司债券 276 万张，每张面值为人民币 100 元，发行价为每张人民币 100 元，募集 资金总额为人民币 276,000,000.00 元，已由承销机构中泰证券股份有限公司于 2022 年 3 月 9 日汇入公司开立在招商银行西安分行曲江支行账号为 12990718041090 ...

陕西盘龙药业集团股份有限公司独立董事工作制度 陕西盘龙药业集团股份有限公司 （2025 年 月） 第一章 总则 第一条 根据《中华人民共和国公司法》（以下简称"公司法"）、《中华 人民共和国证券法》、《上市公司独立董事管理办法》、《深圳证券交易所上市 公司自律监管指引第 1 号—主板上市公司规范运作（2025 年修订）》（以下简 称"监管指引"）的规定，为进一步完善陕西盘龙药业集团股份有限公司（以下 简称"公司"）的法人治理结构，强化对内部董事及经理层的约束和监督机制， 保护中小股东及债权人的利益，促进公司的规范运作，制定本制度。 第二条 独立董事是指不在公司担任除独立董事外的任何其他职务，并与公 司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能妨 碍其进行独立客观判断关系的董事。 第三条 公司建立独立董事制度。独立董事制度应当符合法律、行政法规和 《上市公司独立董事管理办法》的规定，有利于上市公司的持续规范发展、不得 损害上市公司利益。公司应当为独立董事依法履职提供必要保障。 第四条 公司董事会成员中应当有三分之一或以上为独立董事，且其中至少 有一名会计专业人士（会计专业人士是指具有高级 ...

陕西盘龙药业集团股份有限公司董事会议事规则 陕西盘龙药业集团股份有限公司 （2025 年 月） 第一章 总则 第一条 为明确陕西盘龙药业集团股份有限公司（以下简称"公司"）董事 会的职责权限，规范董事会的组织和行为，确保董事会的工作效率和科学决策， 根据《中华人民共和国公司法》 （以下简称"公司法"）、 《深圳证券交易所上市公 司自律监管指引第 1 号—主板上市公司规范运作》和《陕西盘龙药业集团股份有 限公司章程》（以下简称"公司章程"）的规定，制定本规则。 第二条 董事会是公司的常设机构，对股东会负责，执行股东会决议，维护 公司和全体股东的利益，负责公司发展目标和重大经营活动的决策。 第二章 董事 第三条 公司董事为自然人，董事候选人存在下列情形之一的，不得被提名 担任公司董事： （一）《公司法》规定不得担任董事的情形； （二）被中国证监会采取证券市场禁入措施，期限尚未届满； （三）被证券交易所公开认定为不适合担任上市公司董事、高级管理人员等， 期限尚未届满； （四）法律法规、深圳证券交易所规定的其他情形； 违反前款规定选举、委派董事的，该选举、委派或者聘任无效。董事在任职 期间出现本条情形的，公司将解除其 ...

陕西盘龙药业集团股份有限公司董事会薪酬与考核委员会实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》、 《陕西盘 龙药业集团股份有限公司章程》 （以下简称"公司章程"）等规定，公司特设置董 事会薪酬与考核委员会，并制定本实施细则。 第二条 薪酬与考核委员会是董事会按照股东会决议设置的专门工作机构， 主要负责制定、审查公司董事、高级管理人员的薪酬政策与方案，负责制定公司 董事及高级管理人员的考核标准并进行考核，对董事会负责。 第三条 本细则所称董事是指在本公司领取薪酬的董事，高级管理人员是指 董事会聘任的总裁、副总裁、财务负责人、董事会秘书。 第二章 人员组成 第四条 薪酬与考核委员会由三名董事组成，独立董事过半数并担任召集人。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员一名，由独立董事担任，负责主持委 员会的工作。主任委员在委员内选举，并报请董事会备案 ...

陕西盘龙药业集团股份有限公司董事会提名委员会实施细则 陕西盘龙药业集团股份有限公司 （2025 年 8 月） 第一章 总则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结构， 根据《中华人民共和国公司法》、《陕西盘龙药业集团股份有限公司章程》（以下 简称"公司章程"）等有关规定，公司设立董事会提名委员会，并制定本议事规 则。 第二条 董事会提名委员会是董事会按照股东会决议设置的专门工作机构， 主要负责对公司董事、高级管理人员的人选、选择标准和程序进行选择并提出建 议，直接对董事会负责。 第二章 人员组成 第三条 提名委员会委员由三名董事组成，其中独立董事过半数并担任召集 人。 第四条 提名委员会委员由董事长、二分之一以上独立董事或全体董事的三 分之一提名，并由董事会选举产生。 第五条 提名委员会设主任委员一名，由独立董事担任，主任委员负责主持 委员会工作；主任委员在委员内选举，并报董事会备案。 （三）法律、行政法规、中国证监会及公司章程规定的其他事宜。 第九条 提名委员会的提案提交董事会审议决定。 第四章 决策程序 第六条 提名委员会任期与董事会任期一致，委员任期届满连选可以连任。 期间如有 ...